CAR-T therapy Archives - PharmaDeviceNews

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.

Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.

Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.

Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.

Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.

Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.

AvenCell Therapeutics has dosed the first AVC-203 patient in QUADvance. Read what this means for allogeneic CAR-T and B-cell cancer treatment.

AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.

T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.